NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

No, that was addressed by the appropriately addressed update to the Statistical Analysis Plan (SAP) which was filed with regulators for final approval before data lock, and while they were still blinded, as per the relevant regulations, contrary to your constant false assertions.

The fact that too many patients that were placebo wanted the drug and it was considered ethical that they receive it, and that PFS, only a proxy for Ongoing Survival (OS), was discarded because if the way the drug works and how it made it difficult to diagnose recurrence when the drug causes inflammation of brain tumors and distinguishing that from recurrence was not possible at that early time in the trial. So they went not with a hoped for proxy for OS, which often does not predict extended OS, but actual OS. It took way longer to gather that data and did not just happen by accident, as you seem to asset, ignoring that they let the trial go for 18 years, from 2002 to 2020, to get survival data.